Samsung, Sony and Google are among the companies who are shifting smartphone production from China to Southeast Asia
Delhi court refuses to extend chairman’s tenure, leaving the body with just one expert on staff and a growing backlog
A recent announcement is the first time that the Finnish company has drawn attention to the release of SEPs and comes after months of stories about Chinese dominance of the technology
Invalidation efforts in both China and the United States have come up short as the US chip giant faces Chinese infringement claims
Samsung, Canon, Microsoft and Bosch round-out the top five who, between them, are said to own assets worth well in excess of $35 billion
Eight Chinese entities – including leaders in AI, facial recognition and data forensics - added to Bureau of Industrial Security entity list
The big takeaways from a day of deal-making discussions in the heart of Silicon Valley
TSMC hits back against Globalfoundries with countersuits in the US, Germany and Singapore. The headline grabbing dispute takes place as the Lion City attempts to lure more cases with legal reforms
Taiwan’s Personal Genomics is going after an acquisition target of Illumina, the top player in the sequencing space
The company wants to shift disputes to its home jurisdiction and persuade courts there to set a low, China-specific rate
Akorn Inc’s failure to make its case against Allergan and Duke is a reminder that challenging life sciences patentees remains a tough task
Moon Jae-in (centre) made the comments amid an international dispute with Japan. He also said IP can help prevent conglomerates from seizing technology from smaller firms
Europe’s highest court has refused to tackle a long-standing question relating to third-party marketing approval, while its Advocate General has provided confusing guidance on Article 3(a)
The Fourth Amendment to the Patent Law provides for bigger statutory awards and would let judges quintuple awards for punitive purposes
Legal and commercial developments suggest that disputes over increasingly valuable biopharma know-how, proprietary information and data will increase in years to come.
